Showing results (311-320 of 369) with videos related to

Sort By:
Pageof 37
International Journal of Molecular Sciences|January 21, 2023
The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker StudyShobana Anpalakhan, Prerana Huddar, Roya Behrouzi, et al.
British Journal of Cancer|May 15, 2024
Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancerUmberto Malapelle, Natasha Leighl, Alfredo Addeo, et al.
European Journal of Cancer (Oxford, England : 1990)|March 21, 2025
Guidance for discussants of randomized cancer trials at major meetingsElizabeth A Eisenhauer, Omar Abdihamid, Christopher M Booth, et al.
The Lancet. Oncology|February 6, 2025
Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trialsBishal Gyawali, Elizabeth A Eisenhauer, Winette van der Graaf, et al.
Translational Lung Cancer Research|October 17, 2022
Adjuvant treatment for patients with incidentally resected limited disease small cell lung cancer-a retrospective studyKai-Qi Jin, Xiao-Gang Liu, Yan-Hua Guo, et al.
The Lancet. Oncology|September 4, 2025
Importance of responder criteria for reporting health-related quality-of-life data in clinical trials for advanced cancer: recommendations of Common Sense Oncology and the European Organisation for Research and Treatment of CancerIan F Tannock, Madeline Lee Pe, Christopher M Booth, et al.
European Heart Journal Supplements : Journal of the European Society of Cardiology|May 3, 2019
May Measurement Month 2017: an analysis of blood pressure screening results in Nepal-South AsiaShiva Raj Mishra, Nipun Shrestha, Indra Prasad Poudyal, et al.
Cancer Immunology, Immunotherapy : CII|November 1, 2020
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2Michael Mark, Patrizia Froesch, Eric Innocents Eboulet, et al.
Frontiers in Oncology|June 16, 2023
Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysisShobana Anpalakhan, Prerana Huddar, Roya Behrouzi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapyMarco Ladetto, Daniela Drandi, Mara Compagno, et al.
Pageof 37